The efforts proposed describe the thorough investigation of a class of dendrimers to determine whether these monodisperse, engineerable macromolecules are suitable vehicles for drug delivery. Their size suggests that the EPR effect can be exploited to target tumors. The ability to decorate these architectures with homing peptides allows for the investigation of """"""""magic bullet"""""""" stategies. The proposal focuses on Pt-coordination complexes, as the collaborator has great interest in this agent. The biological studies will be executed by the collaborator in conjunction with students from the PI's laboratory.This proposal addresses two specific aims: 1) Can the dendrimers be targeted to tumors using passive and/or active strategies? The enhanced permeability and retention of polymers by tumors offers a passive mechanism for targeting these tissues for destruction. Attaching homing peptides to the polymeric drug delivery vehicle offers an additional active strategy to further discriminate the diseased tissue from host tissue. These experiments will be executed by looking at the biodistribution of labeled dendrimers that differ in size and composition. Strategies for screening compositions efficiently, and evaluating libraries of homing peptides are described. 2) Can the dendrimers be loaded with cytotoxins and display suitable anticancer activity? Platinum will be loaded using dendrimers through pendant malonate groups. Release from the malonate is triggered in response to a change in pH. Other cytotoxins will be conjugated using reversible or biolabile linkages. The ability of these dendrimers to noncovalently sequester anticancer agents is also explored.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
1R01GM064560-01A1
Application #
6547605
Study Section
Medicinal Chemistry Study Section (MCHA)
Program Officer
Fabian, Miles
Project Start
2002-08-01
Project End
2006-07-31
Budget Start
2002-08-01
Budget End
2003-07-31
Support Year
1
Fiscal Year
2002
Total Cost
$254,625
Indirect Cost
Name
Texas A&M University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
047006379
City
College Station
State
TX
Country
United States
Zip Code
77845
Lim, Jongdoo; Kostiainen, Mauri; Maly, Jan et al. (2013) Synthesis of large dendrimers with the dimensions of small viruses. J Am Chem Soc 135:4660-3
Lim, Jongdoo; Pavan, Giovanni M; Annunziata, Onofrio et al. (2012) Experimental and computational evidence for an inversion in guest capacity in high-generation triazine dendrimer hosts. J Am Chem Soc 134:1942-5
Barata, Teresa; Teo, Ian; Lalwani, Sanjiv et al. (2011) Computational design principles for bioactive dendrimer based constructs as antagonists of the TLR4-MD-2-LPS complex. Biomaterials 32:8702-11
Merkel, Olivia M; Zheng, Mengyao; Mintzer, Meredith A et al. (2011) Molecular modeling and in vivo imaging can identify successful flexible triazine dendrimer-based siRNA delivery systems. J Control Release 153:23-33
Lo, Su-Tang; Stern, Stephan; Clogston, Jeffrey D et al. (2010) Biological assessment of triazine dendrimer: toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct. Mol Pharm 7:993-1006
Lim, Jongdoo; Venditto, Vincent J; Simanek, Eric E (2010) Synthesis and characterization of a triazine dendrimer that sequesters iron(III) using 12 desferrioxamine B groups. Bioorg Med Chem 18:5749-53
Lim, Jongdoo; Mintzer, Meredith A; Perez, Lisa M et al. (2010) Synthesis of odd generation triazine dendrimers using a divergent, macromonomer approach. Org Lett 12:1148-51
Merkel, Olivia M; Mintzer, Meredith A; Simanek, Eric E et al. (2010) Perfectly shaped siRNA delivery. Ther Deliv 1:737-42
Lim, Jongdoo; Pellois, Jean-Philippe; Simanek, Eric E (2010) A retro-inverso TAT-like peptide designed to deliver cysteamine to cells. Bioorg Med Chem Lett 20:6321-3
Venditto, Vincent J; Simanek, Eric E (2010) Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharm 7:307-49

Showing the most recent 10 out of 27 publications